Paradoxical Depressive Response to Intranasal Esketamine in Treatment-Resistant Depression: A Case Series.
The American journal of case reports December 28, 2024 Jose A Ontiveros-Sánchez de la Barquera, Luis Alberto De La Garza García, Silvia Viridiana Esquivel García et al. 2 citations
BACKGROUND Esketamine is the only pharmacological agent with glutamatergic neuromodulator properties approved by the US Food and Drug Administration and European Medicines Agency to enhance the effects of serotonin selective or serotonin and norepinephrine reuptake inhibitors. Treatment-resistant depression (TRD) is a challenging and prevalent condition in the psychiatric field, in which...